Literature DB >> 11779098

Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants.

M Akisu1, S Tuzun, S Arslanoglu, M Yalaz, N Kultursay.   

Abstract

In the present investigation, we studied the effect of recombinant human erythropoietin (r-HuEPO) on serum malondialdehyde (MDA) as an index of lipid peroxidation, related to iron-catalyzed free radical reaction and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities in very-low-birth weight (VLBW) infants. Forty premature infants, at gestational ages were less than 33 weeks and birthweights were less than 1,500 g, were enrolled in the study. The study population was randomly divided into 2 groups. Twenty infants in Group 1 (treatment group) were given r-HuEPO, and 20 infants in Group 2 served as the control. r-HuEPO treatment (750 U/kg a week) was initiated on the 10th day of life and continued for 6 weeks. Preterm infants given erythrocyte transfusions during the study were excluded from the results. Serum ferritin and MDA levels, and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities were analyzed at the end of the first week of life (at the beginning of the study). Subsequently, serum ferritin, and MDA levels were measured at the end of the 3rd and the 6th week. SOD, CAT, and GPX activities in the hemolysate were analyzed at the end of the 4th week. Six infants in the control group and 1 infant in the r-HuEPO group received transfusions through the end of the study, and these infants were excluded from the results. Significantly decreased serum ferritin concentrations were found in the r-HuEPO group compared to those in the control group both at the end of the 3rd and the 6th week (P < 0.05, and P < 0.01, respectively). In addition, serum MDA levels were also significantly reduced in Group 1 compared to control both at the end of the 3rd and the 6th week (P < 0.01 and P < 0.05, respectively). A good correlation was found between serum MDA and ferritin levels in Group 1. When the 2 groups were compared with respect to activities of SOD, CAT, and GPX at the end of the 4th week, no differences were observed. Our findings in this study show that administration of r-HuEPO significantly decreases lipid peroxidation, but does not affect erythrocyte antioxidant enzyme(s) activities in preterm infants. The mechanism responsible for the r-HuEPO-induced decrease in lipid peroxidation may concern inhibition to iron-catalyzed free radical reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11779098     DOI: 10.18926/AMO/31997

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  17 in total

1.  Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats.

Authors:  Péter Monostori; Gabriella F Kocsis; Zsuzsanna Ökrös; Péter Bencsik; Orsolya Czétényi; Zoltán Kiss; Balázs Gellén; Csaba Bereczki; Imre Ocsovszki; Judit Pipis; János Pálóczi; Márta Sárközy; Szilvia Török; Ilona S Varga; István Kiss; Eszter Fodor; Tamás Csont; Péter Ferdinandy; Sándor Túri
Journal:  Clin Exp Nephrol       Date:  2012-12-06       Impact factor: 2.801

2.  One-year experience in the retinopathy of prematurity: frequency and risk factors, short-term results and follow-up.

Authors:  Sariaydin Mehmet; Atlihan Fusun; Calkavur Sebnem; Olukman Ozgur; Ercan Gulten; Ozturk Arif Taylan; Kaya Kilic Fatma; Gokaslan Filiz; Altinyaprak Derya; Malatyali Rana
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

3.  Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Authors:  Ensari Guneli; Zahide Cavdar; Huray Islekel; Sulen Sarioglu; Serhat Erbayraktar; Muge Kiray; Selman Sokmen; Osman Yilmaz; Necati Gokmen
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

4.  A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.

Authors:  Robin K Ohls; Robert D Christensen; Beena D Kamath-Rayne; Adam Rosenberg; Susan E Wiedmeier; Mahshid Roohi; Conra Backstrom Lacy; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Ron Schrader; Jean R Lowe
Journal:  Pediatrics       Date:  2013-06-17       Impact factor: 7.124

Review 5.  Necrotizing enterocolitis: a multifactorial disease with no cure.

Authors:  Kareena-L Schnabl; John-E Van Aerde; Alan-Br Thomson; Michael-T Clandinin
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

6.  Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings.

Authors:  Erkan Kaptanoglu; Ihsan Solaroglu; Ozerk Okutan; H Selcuk Surucu; Filiz Akbiyik; Etem Beskonakli
Journal:  Neurosurg Rev       Date:  2003-08-14       Impact factor: 3.042

7.  Iron therapy for preterm infants.

Authors:  Raghavendra Rao; Michael K Georgieff
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

Review 8.  Recent trends in erythropoietin-mediated neuroprotection.

Authors:  Ronald J McPherson; Sandra E Juul
Journal:  Int J Dev Neurosci       Date:  2007-09-04       Impact factor: 2.457

9.  Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.

Authors:  Sanjay M Aher; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2019-02-15

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.